Patients with autoimmune hepatitis (AIH) almost inevitably require lifelong immunosuppressive treatment. There is genuine concern about the efficacy and tolerability of the current standard combination therapy of prednisolone and azathioprine. Mycophenolate mofetil (MMF) has emerged as an alternative option. The aim of this study was to compare MMF to azathioprine as induction therapy. In this 24-week, prospective, randomised, open-label, multicentre superiority trial, 70 patients with treatment-naive AIH received either MMF or azathioprine, both in combination with prednisolone. The primary endpoint was biochemical remission defined as normalisation of serum levels of alanine aminotransferase and immunoglobulin G after 24 weeks of treatment. Secondary endpoints included safety and tolerability. Seventy patients (mean 57.9 years (standard deviation (SD) 14.0); 72.9% female) were randomly assigned to the MMF plus prednisolone (n=39) or azathioprine plus prednisolone (n=31) group. The primary endpoint was met in 56.4% and 29.0% of patients assigned to the MMF group and the azathioprine group, respectively (difference, 27.4 percentage points; 95% confidence interval (CI), 4.0 to 46.7; p=0.022). The MMF group exhibited higher complete biochemical response rates at 6 months (72.2% vs. 32.3%; p=0.004). No serious adverse events occurred in patients who received MMF (0%) but serious adverse events were reported in four patients who received azathioprine (12.9%) (p=0.034). Two patients in the MMF group (5.1%) and eight patients in the azathioprine group (25.8%) discontinued treatment owing to adverse events or serious adverse events (p=0.018). In patients with treatment-naive AIH, MMF with prednisolone achieved a significantly higher rate of biochemical remission at 24 weeks compared to azathioprine combined with prednisolone. Azathioprine use was associated with more (serious) adverse events leading to cessation of treatment, suggesting superior tolerability of MMF. This randomised controlled trial directly compares azathioprine and mycophenolate mofetil (MMF), both in combination with prednisolone, for the induction of biochemical remission in treatment-naive patients with autoimmune hepatitis (AIH). Achieving complete remission is desirable to prevent disease progression. Patients assigned to the MMF group reached biochemical remission more often and experienced fewer adverse events. The findings in this trial may contribute to the re-evaluation of international guidelines for the standard of care in treatment-naive patients with AIH. #NCT02900443.
Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y12-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—particularly in an outpatient setting—remains limited. We conducted a proof-of-concept study to evaluate the feasibility of CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel through point-of-care (POC) PGx testing in the community pharmacy. Multiple feasibility outcomes were assessed. Overall, 144 patients underwent CYP2C19 PGx testing in 27 community pharmacies. Successful test results were obtained in 142 patients (98.6%). De-escalation to clopidogrel occurred in 19 patients (20%) out of 95 (67%) eligible for therapy de-escalation, which was mainly due to PGx testing not being included in cardiology guidelines. Out of the 119 patients (84%) and 14 pharmacists (100%) surveyed, 109 patients (92%) found the community pharmacy a suitable location for PGx testing, and the majority of pharmacists (86%) thought it has added value. Net costs due to PGx testing were estimated at €43 per patient, which could be reduced by earlier testing and could turn into savings if de-escalation would double to 40%. Although the observed de-escalation rate was low, POC CYP2C19-guided de-escalation to clopidogrel appears feasible in a community pharmacy setting.
22 December 2025 in Clinical Pharmacology & Therapeutics
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5 *6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%). We conducted a retrospective, longitudinal cohort study using real‐world data from 1,461 adult kidney transplant recipients across 67 countries, analyzing 4,293 dose‐normalized 24‐hour area‐under‐the‐curve (AUC 0‐24 ) measurements of tacrolimus. Patients with CYP3A5* 1/*1 were excluded. Linear mixed‐effects models (LME) were used to assess the association between CYP3A5* 6 carriage and tacrolimus exposure, adjusting for clinical factors and ancestry using both HLA‐based principal components and country of birth. CYP3A5 *6 carriers had a 17% lower dose‐normalized AUC 0‐24 than CYP3A5 *3 carriers ( P = 0.015). Sensitivity analyses using dose‐normalized trough concentrations (C 0 ) confirmed these findings, with a 20% lower exposure in CYP3A5 *6 carriers ( P = 0.011). An interval‐based analysis demonstrated persistently lower tacrolimus exposure across the first post‐transplant year. All CYP3A5 *6‐containing genotypes showed significantly lower dose‐normalized AUC 0‐24 compared to CYP3A5 *3/*3, the most common genotype in European populations, with the largest reductions observed in CYP3A5 *1/*6 (−39%; P < 0.001) and CYP3A5 *3/*6 (−18%; P = 0.006). African origin, defined by country of birth, was independently associated with a 23% higher AUC 0‐24 ( P < 0.001). This is the first study to demonstrate a differential effect on tacrolimus exposure between the CYP3A5 *6 and CYP3A5 *3 loss‐of‐function alleles. Our results may help bridge the ethnicity gap, advance the applicability of pharmacogenomic findings, and promote health equity.
The CAMARO trial demonstrated superior short-term tolerability and response rates of mycophenolate mofetil (MMF) versus azathioprine (AZA), both combined with prednisolone, in treatment-naïve autoimmune hepatitis (AIH). We evaluated long-term outcomes. Patients enrolled in the multicenter randomized CAMARO trial were retrospectively followed for up to 3 years after treatment initiation. Co-primary endpoints were trial-assigned treatment with normalized alanine aminotransferase (ALT) at 3 years and time to biochemical response (normalization of ALT and immunoglobulin G). Three-year follow-up was available for 67 patients (96%; 30 AZA, 37 MMF). At 3 years, 57% versus 76% remained on trial-assigned treatment with normalized ALT (p = 0.099). Median time to biochemical response was 64 versus 16 weeks (adjusted HR 2.74, 95% CI 1.49-5.06; p = 0.001). Among patients without ALT normalization at 24 weeks, 6/12 AZA-treated and 6/11 MMF-treated patients subsequently normalized ALT. Among patients remaining on randomized treatment at 24 weeks, subsequent treatment discontinuation occurred in 5/24 (21%) with AZA and 7/37 (19%) with MMF. Steroid-free ALT normalization (64% vs. 66%) and adverse event rates during year 3 (70% vs. 74%) were comparable (both p > 0.05). Five-year liver-related event-free survival was 70% (95% CI 55-93%) with AZA and 85% (95% CI 71-100%) with MMF (p = 0.080). MMF was associated with faster biochemical response and numerically better overall tolerability. Among patients tolerating their assigned treatment during the initial treatment phase, subsequent outcomes were comparable between AZA and MMF. The substantial treatment burden with both therapies highlights the need for improved treatment options. NCT02900443.
Background and Objective Venetoclax shows substantial pharmacokinetic (PK) variability and frequent toxicity, making it an archetypal candidate for PK monitoring. Capillary microsampling may facilitate decentralized PK monitoring of venetoclax. However, clinical validation is lacking. This study aimed to clinically validate capillary microsampling for venetoclax and to assess the feasibility of home-based self-microsampling. Methods Adult patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) receiving oral venetoclax therapy provided paired venous plasma and capillary samples using dried blood spot (DBS) and volumetric absorptive microsampling (VAMS) devices. We evaluated individualized hematocrit-based microsample-to-plasma correction models and previously published whole-blood-to-plasma conversion strategies. Agreement and predictive performance were assessed according to international microsampling validation criteria. The feasibility of home-based self-microsampling was evaluated by examining patients’ ability to collect samples independently, the proportion of usable returned samples, and device usability. Results A total of 25 patients contributed 64 sets of paired venous plasma, DBS, and VAMS samples. Uncorrected DBS and VAMS venetoclax concentrations underestimated plasma concentrations (mean bias − 21% and − 14%, respectively) and showed clear hematocrit dependence. Individualized hematocrit–plasma/microsample ratio models showed excellent performance, with 95% of DBS and 91% of VAMS concentrations within ± 20% of plasma and low bias and imprecision across all validation metrics. Literature-based correction strategies showed lower acceptance rates and wider limits of agreement. Among patients attempting self-microsampling, 18 of 21 sampled independently, 76% of returned DBS/VAMS samples were suitable for analysis, and usability ratings were higher for VAMS than DBS. Conclusions Capillary microsampling enables accurate venetoclax quantification in patients with AML and CLL when individualized hematocrit-based microsample-to-plasma conversion is applied. Both DBS and VAMS met international validation criteria, and home-based self-microsampling proved feasible. Venetoclax home-based self-microsampling warrants further study as a tool for decentralized PK monitoring.